I-SPY2.2: RT-DXd May Reduce Chemotherapy Exposure in Immune-Positive Early Breast Cancer
Neoadjuvant treatment with the immune-directed bispecific antibody rilvegostomig plus the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (RT-DXd) demonstrated “promising” activity with mostly low-grade adverse events in patients with immune-positive, ERBB2-negative early breast cancer, according to findings from the adaptively randomized, multicenter phase II I-SPY2.2 platform trial published in JAMA Oncology. Among those who achieved a pathologic complete response, more than half avoided standard chemotherapy.
Conversely, immune-negative tumors responded poorly, the investigators wrote.
The results “support further evaluation in biomarker-selected populations,” they commented.
Study Details
I-SPY2.2 evaluated multiple experimental regimens in parallel at 30 sites across the United States. This RT-DXd analysis focused on patients with high-risk stage II/III ERBB2-negative early breast cancer, including those with ERBB2-low/-ultralow tumors, stratified by hormone receptor status and response-predictive subtypes.
Following initial 2:1 randomization to the experimental track or concurrent control arm and subsequent assignment to RT-DXd within the experimental track, the analysis population comprised 182 patients; 105 received RT-DXd and 77 received control treatment. Patients in the RT-DXd experimental arm received up to three sequential treatment blocks based on response and subtype:
Block A: RT-DXd
Block B: Taxane-based therapy with or without immunotherapy
Block C: Doxorubicin–cyclophosphamide with or without immunotherapy.
Patients in the control arm began with block B and could subsequently receive block C.
Pathologic complete response was identified as the primary endpoint. Safety assessments evaluated adverse events, with particular attention to interstitial lung disease.
Key Findings
Among patients who received RT-DXd in block A, the modeled pathologic complete response rate was 54% in immune-positive tumors, meeting the predefined threshold for success. The investigators reported similar pathologic complete response rates in hormone receptor–positive, immune-positive disease (57%) and hormone receptor–negative, immune-positive disease (52%).
Overall pathologic complete response rates across all treatment blocks were reported as similar to those observed in the control arm; however, among immune-positive patients who achieved pathologic complete response, 62% required only block A, and 97% did not receive anthracycline-based chemotherapy.
Fatigue and nausea were the most common adverse events.
Serious adverse events included pulmonary embolism and interstitial lung disease, each occurring in 2.9% of patients treated with RT-DXd. Interstitial lung disease of any severity occurred in 12.4% during block A treatment, including one grade 3 event, and was detected early through serial chest CT monitoring.
The investigators concluded, “The trial results suggest that RT-DXd is highly active in immune-positive disease regardless of hormone receptor or ERBB2-low/-ultralow status, with mostly low-grade toxic effects, and it could be a shorter, less toxic neoadjuvant therapy option; whereas immune-negative tumors responded poorly, highlighting the need for new therapies.”
“Larger neoadjuvant trials are needed, with [health-related quality of life] and recovery time as critical endpoints,” they continued. “Refining our understanding of what determines response is crucial; I-SPY2.2 is a biomarker-rich trial that is instrumental to this effort.”
Laura J. Esserman, MD, MBA, of the University of California, San Francisco, is the corresponding author of the article in JAMA Oncology.
Disclosure: The study was supported by the National Cancer Institute and others. For full disclosures of the study authors, visit jamanetwork.com.